ABOS · NASDAQ · Biotechnology

Acumen Pharmaceuticals (ABOS)

Develops sabirnetug, an investigational antibody for early symptomatic Alzheimer’s disease.

$2.60
After hours−0.04 (−1.70%)
At close$2.65(+2.12%)